Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Lymphoid 1Gastrointestinal 1Breast 1

Conditions

Sarcoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Paclitaxel 162Fulvestrant 155Trastuzumab 154pembrolizumab 144Letrozole 136Carboplatin 118pertuzumab 104Cyclophosphamide 102Capecitabine 101Specimen Handling 100Anastrozole 90palbociclib 85abemaciclib 81Magnetic Resonance Spectroscopy 81exemestane 76Tamoxifen 75Docetaxel 75ribociclib 74trastuzumab deruxtecan 69Radiotherapy 62Biopsy 60Surveys and Questionnaires 56Gemcitabine 52130-nm albumin-bound paclitaxel 52sacituzumab govitecan 50olaparib 50Standard of Care 50Blood Specimen Collection 50Taxes 47Doxorubicin 46

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
crenigacestat × Breast × 1 year × Clear all
NCT02784795 2025-08-21

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
94 enrolled 28 charts
BreastGastrointestinalSarcoma

Breast Neoplasms, Colonic Neoplasms, Sarcoma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡